Member Info for MR.Spacetomato

Sorento needs a machine to test the sample. Nah

Wasn't there a list of top contenders for the saliva tests in that Rockerfeller fella paper?

ST

Yes, I saw that.

Ok. Still not covered.

One thing we have in common at least , we both want this share to fly upwards.

Cheers

Ok, you unbelievers. I can only see that there are plenty of small buys going through, yet the price is being held in the current range. Sells being absorbed by mms to fill another order. Let's see if we don't get another TR1 soon to show this.

Scarabbeatle, :0).

"800 - Prepare for an increase in trading volume, and 600 - Apply resistance at the ASK price to keep the price from increasing".

In my view we should see the price moving up before close trading to break the 220p.

Good luck all.

Woodstock1970,

Hi. I can see your point of 50/50, but I still believe there's something here on the codes. For instance, you want to buy some sng shares. What do you do? I know for me I look at how much cash I have to invest and place an order. What are the likelihood of it getting me exactly 500, 800 or 600 shares?

Sure, it may be someone just picking 500 because it is what they need for some reasons (they like round numbers), or the are rounding up an order.

Anyway, if MMs wish to quickly send a message to each other it could be the faster way to do it. Now, for me where there is smoke...

Nevermind..

St

Mrninjazx6,

What is your mental age? 5?

I do hold SNG by the way, now 33% of my Portfolio so it was certainly not a deramp, which you may have thought the case to be, and led you to vomit your garbage.

Many may not believe in codes, but I do and you can see ( not you Mrninjazx6, of course) from my previous posts that I was correct on the codes. Anyway, nevermind.

As per you Mrninjazx6, don't bother to reply to my post as I will not be able to read them as I am placing Mrninjazx6 in the garbage filter can.

Good luck to holders.

ST

 800 - Prepare for an increase in trading volume
600 - Apply resistance at the ASK price to keep the price from increasing.

Just seen them popping up.

Cheers

St

Chengdo, that, I think, has been the approach AS has taken from the start. Frustrating for us sometimes as it is our money we are trusting and supporting them, but news will come when they are ready. I suppose the gains here will equate to the stress levels each one of us experienced whilst investing in avacta times the monetary risks we all accepted to bear.

Not long to wait now.

We should not forget the mass spectrometry Bams test revenue as well.

There are just over 1200 hospitals in the uk. Imagining that most would have one machine, and taking say only 200 of them churning 1,000 tests a day, that would be 200,000 people being tested a day in hospitals drive through arrangement.

Say Adeptrix and Avacta charge £2 per test, that would be £1,400,000 a week or £5,600,000 a month. That's just from hospital track and trace settings.

Integumen's trials should also bear fruit soon and the project expanded nationwide and going global.

The best thing I find is that we should have MADE IN THE UK labelled on it, and not some cheap made in china crap. I am not buying anything made in china and believe me, it almost impossible.

ST

Thanks guys for your replies. I guess it is balanced the views here, and I can see all angles. The opportunity is there and with the right product in the app environment one can make millions if you get in at the right price.
As I said, this company looks really interesting and the concept of a passporting-type app is indeed the future. This awful covid has opened up another opportunity here so it's a share to watch closely.

Thanks again and let's hope we get news soon.

Good luck all.

ST

JSP123,

Good afternoon to you and thank you for your time to reply to my query. Good to know a fellow investor is replying, great minds and all that :0).
Yes, I read the RNSs and too have added the weeks. To have an effective app to tackle the track and trace on time is a plus. To have someone with deep pockets investing here is also reassuring.
I have placed Tcea in my radar now to see what the share price and volume will do in the next few weeks and decide what to do.
In the time being I wish you really well in your investments and here too.
Take care JSP123.
Speak soon
ST

Who needs advertising? All we need is to send GAZALA69 to all ladies hair sloons and RK's £5 a share will arrive much earlier.

Toes hair clipping maybe?

Hi all,

I am invested in covid pharmas at the moment but still have some free cash wanting a potential blockbuster share to buy. I thought to diversify my holdings and after some research I cam across ctea. I did like the CEO's interview posted a while back on this BB and it seems the company is not just a one trick pony.

The fluctuations on the share price here would be really interesting for a day trader, but hindered by the spread. However, the potential spike ctea would get should any good news break here is very enticing. Assuming the current African trials plan out to be good and another contract lands the returns could be substantial. It is risky but one has to take risks sometimes to make it big.

My question would be, how confident are the shareholders of imminent news here, seeing a good reliable app can be attractive to countries in need of a track and trace app?

Thanks in advance for any reply and good luck.

ST

PS: sure I do my own research and it is based on that that I invest, but it would be nice to have a general perception from the BB.

CS,

We are forgetting one important thing, and that's the LFA kit will and should not be used only for covid 19. Once we get the kit eventually proved and certified it can be modified to target other tropical diseases and other viruses.

We will be the reference for highly specific and sensitivity test kits with a world renowned brand. What price can you put on that Mr Americanstar?

I wish I had 145,000 shares.

ST

V2cola,

That shows why Avacta's "slow" progress has such importance and given us a better chance to be ready and when "the readiness is all"! See Sona and the FDA's ridiculous high standard guidelines of 95% sensitivity for DIY tests published after Sona's got their kit out.

ST

OPhidian,

Wait till Trump gets a "wiff" of the novel idea you are laughing at! We may not be "qualified" in affimer science like some, but I can assure you we can give Trump a few extra votes! Don't cancel the bleach order just yet, mister!

...

Closing in on a major inflection point?
Having recently put the necessary financial resources in place, Avacta now
appears to be rapidly closing in on a number of major inflection points. While
timing remains of the essence for any COVID-19 test developments, billion-dollar
markets are available right now to first movers capable of delivering an approved
antigen testing product that comes with the necessary scale, reliability and ease
of use. While highlighting the development potential offered through Affimer
molecules, today’s news covers just one of a number of ambitious and rapidly
developing projects Avacta presently has underway, and all of which address
areas of major growth potential. In this respect, it is important to note that
Avacta’s COVID-related developments are in addition to the significant potential
value of the Group’s existing therapeutics business which is focused on
developing novel cancer therapies, both in-house and with partners such as
Daewoong Pharmaceutical, Moderna Therapeutics, ADC Therapeutics and LG
Chem Life Sciences, using its two proprietary drug development platforms:

Affimer® and pre|CISIONTM. Although, given the development stage and dynamic background, it is not presently
possible to award specific, high confidence value to any of these, successful delivery could further multiply
Avacta’s current market valuation in the relatively near-term.
Clinical Validation
Avacta aims to begin clinical validation of the SARS-CoV-2 antigen test as soon as possible by using the first pilot
batches generated as part of the technology transfer process for these studies.
In parallel with these clinical validation studies, which will be run within the UK government’s CONDOR programme
and potentially with other collaborators globally, BBI will work with Avacta and Cytiva to produce the additional
technical documentation that is required for CE marking of the final product and subsequent launch.
Avacta’s diagnostics business has also invested in order to accelerate its securing of ISO 13485 accreditation. This
oversees a Quality Management System compliance standard for the Medical Device industry which, in turn, will
streamline CE marking and other regulatory approval processes for the Group.

The end

Sorry if already posted.

ST

Avacta Group plc
Avacta has announced its appointment of BBI Solutions, part of BBI Group (‘BBI’),
to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being
developed with its partner, Cytiva (formerly part of GE Healthcare Life Sciences).
This follows news from 22 April 2020 , that the partnership had progressed rapidly
with several highly specific Affimer®
reagents having already been successfully
generated. Anticipating very high demand for the test, BBI has now been selected
as a preferred manufacturing partner, while Avacta also continues discussions
with other high volume producers with a view to ensuring access to additional
capacity that may be needed to address global needs both now and in the future.
Developing a potential ‘game changing’ product
Simplicity, scale and early detection are all critical factors that have to be
considered by users seeking rapid testing and diagnostics as a positive step
towards controlling the current global health crisis. Improvements in ease of use
created through the Avacta-Cytiva partnership, which offer rapid, reliable testing
while eliminating the invasive nasopharyngeal swab protocol without
compromising performance, has potential to become a ‘game changer’ in the next
phase of the global pandemic response.
Realistically, the offer of mass testing with low cost disposable tests, whilst also
eliminating the expense/complexity of extraction through provision of a less
invasive sample collection process, is most likely to open testing access to wider
global communities. Indeed, given that most government agencies/health
practitioners consider frequent testing of a large percentage of the population to be
the best path forward, and critical for getting the global economy back to work, the
near and longer-term market opportunity presented is clearly very large indeed.
Appointing the ideal manufacturer
BBI Solutions is a leading global developer and manufacturer of raw materials and
finished test products for the in-vitro diagnostics market, with manufacturing sites
in five different countries, spanning four continents. The manufacturing
agreement between Avacta and BBI comprises the accelerated development and
validation of a scaled-up manufacturing process that has the potential to ramp up
to a production capacity of millions of tests per month. Avacta, Cytiva and BBI are
now undertaking a technology transfer that covers the prototype along with the
related manufacturing procedures for the saliva-based test.

Continue...